NCT05659628View on ClinicalTrials.gov

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Diffuse Large B-cell Lymphoma
Interventions
COMBINATION_PRODUCT

CD19-7×19 CAR-T combined with Tislelizumab

Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.

Trial Locations (2)

310009

RECRUITING

The Second Affiliated Hospital of Zhejiang University, Ningbo First Hospital, Hangzhou

315010

RECRUITING

Ningbo First Hospital, Ningbo

All Listed Sponsors
collaborator

Zhejiang University

OTHER

lead

Ningbo No. 1 Hospital

OTHER